US FDA Makes Final Decision On 'Inordinate' Out-Of-State Compounding
Under the US FDA’s final MOU on interstate compounding, states are given more time to decide whether to sign the agreement and investigate complaints of adverse events associated with drugs compounded by 503A pharmacies. Agreement draws mixed reactions from pharmacy groups.
You may also be interested in...
There is scant evidence to support use of compounded topical pain creams, and tougher controls are needed to regulate 503A pharmacies, according to a recent study by the National Academies.
After discovering one firm suppressed over 4,000 compounded-hormone adverse event reports, agency leans on compounders and outsourcers to improve reporting.
The US FDA’s revised draft MOU on interstate compounding, which stipulates new controls to ensure that pharmacies do not ship an “inordinate” amount of drugs across state lines, needs strong state oversight and robust information collection to work, say some groups commenting on the agreement. Yet two members of Congress are challenging the MOU on the grounds that some states and state boards of pharmacy lack the regulatory authority to implement the agreement.